Roger Schibli received his PhD in organic chemistry at the University of Basel, followed by a post-doctoral fellowship at the University of Missouri-Columbia. Since 2010, Roger Schibli holds a full professorship at the Department of Chemistry and Applied Biosciences (ETH Zurich) and heads the Center for Radiopharmaceutical Sciences ETH-PSI-USZ. Roger Schibli pioneered the use of transglutaminases for the site-specific modification of antibodies in his labs at PSI and ETH Zurich more than 10 years ago and is author of many key scientific publications in that area of research. He supports us with his in-dept knowledge about enzymatic modifications of antibodies as well as linker design which is core to the Araris Linker Technology.
Current role
AI Scientist at Ekkel AI
Research Scientist at Mazumdar Shaw Medical Foundation (MSMF)
Research Resources Team Member at Australian Medical Students' Association
Data Science Vice President at PS AI Labs
Co-founder & CEO At 369 Labs | Beat Energy at Embertec
Access the worlds's biggest network of public org charts
Learn more